Peripheral Blood-Derived Mesenchymal Stem Cells: Candidate Cells Responsible for Healing Critical-Sized Calvarial Bone Defects

Abstract

A coculture system that routinely produces a group of cells from adult peripheral blood is presented. A subset of CD45− cells with a fibroblastic morphology was isolated. The CD45− fibroblastic cells are the first peripheral blood‐derived cells that fulfill the criteria of mesenchymal stem cells as defined by the International Society for Cellular Therapy.

Effect of Stem Cells and Gene Transfected Stem Cells Therapy on the Pancreas of Experimentally Induced Type 1 Diabetes

“…The previous results indicated autoimmune destruction of the insulin producing β-cells as documented by Martinov et al (30). It was proved that MSCs exhibit a surface marker profile ＋ve for CD44 (31). It was added that diabetes negatively impacts on functional properties of tissue resident SCs with consequent defective regeneration (32).…”

Comparative Histological Study on the Effect of Stem Cells, and Gene Modified Stem Cells in Experimentally-Induced Diabetes Type 1 Cardiomyopathy

“…In accordance, MSCs retrieved from bone marrow or adipose tissue hold great promise to enhance repair of damaged tissues. They exhibit a surface marker profile +ve for CD44, CD90 and CD105 [34] .…”

Uterine cells—an immunoprivileged cell source for therapy—but are they for everyone?

“…It would be interesting to see whether an MHC I (neg) cell population could be isolated from the more readily available bone marrow or adipose MSCs and whether it too would have the increased therapeutic potential shown by the MHC I (neg) uterine cells. Indeed, a similarly immunoprivileged cell type in the recently identified MSC populations in peripheral blood [51] and urine [52] would present an even more accessible source of cells and really open up the prospect of allogeneic cell therapy for all. Despite extensive research, both in the lab and the clinic, effective stem cell therapy for cardiac repair remains elusive, partly due to the persistent problem of limited donor cell retention.…”